Wave Life Sciences Ltd. (NASDAQ:WVE) CFO Sells $154,314.00 in Stock

Wave Life Sciences Ltd. (NASDAQ:WVE) CFO Kyle Moran sold 17,146 shares of the stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the completion of the sale, the chief financial officer now directly owns 19,777 shares of the company’s stock, valued at approximately $177,993. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Wave Life Sciences Trading Up 3.4 %

Shares of NASDAQ WVE opened at $8.29 on Monday. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $9.92. The firm’s 50 day simple moving average is $6.03 and its two-hundred day simple moving average is $5.85.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.99%. The company had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $24.80 million. During the same quarter in the previous year, the firm posted ($0.20) EPS. On average, equities analysts anticipate that Wave Life Sciences Ltd. will post -1.04 EPS for the current fiscal year.

Institutional Trading of Wave Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its stake in shares of Wave Life Sciences by 50.2% during the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock worth $45,000 after acquiring an additional 2,451 shares during the last quarter. Profund Advisors LLC purchased a new stake in shares of Wave Life Sciences during the second quarter worth approximately $53,000. Principal Financial Group Inc. acquired a new stake in Wave Life Sciences in the 2nd quarter valued at about $74,000. Mackenzie Financial Corp lifted its position in Wave Life Sciences by 13.6% during the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after buying an additional 1,905 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Wave Life Sciences in the 4th quarter valued at about $86,000. Institutional investors own 89.73% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on WVE shares. B. Riley started coverage on shares of Wave Life Sciences in a research report on Thursday, September 19th. They set a “buy” rating and a $11.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Wave Life Sciences in a research report on Friday. They issued an “overweight” rating and a $13.00 target price for the company. Mizuho reissued an “outperform” rating and set a $19.00 target price on shares of Wave Life Sciences in a report on Tuesday, June 25th. Finally, HC Wainwright boosted their price objective on shares of Wave Life Sciences from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.